Community Practice Connections™: “D” is for Diagnosis: Solving the Mystery of Rare Hematologic Disorders

Community Practice Connections™: “D” is for Diagnosis: Solving the Mystery of Rare Hematologic Disorders is organized by Physicians' Education Resource, LLC (PER) and will be held from Feb 28, 2019 - Feb 28, 2020. This Course has been approved for a maximum of 1.5 CME Credits.

Target Audience:
This activity is intended for medical oncologists, hematologists, and other oncology healthcare professionals interested in understanding the current treatment guidelines and diagnostic strategies for patients who present with hematologic symptoms of unknown origin. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other healthcare professionals are also invited to participate.

Activity Overview:
Hematologists and primary care physicians play a pivotal role in the diagnosis of disorders and management of patients who present with hematologic symptoms of unknown origin. This program is designed to raise your awareness of the rare hematologic disorders Gaucher disease, paroxysmal nocturnal hemoglobinuria, thrombotic thrombocytopenic purpura, and immune thrombocytopenia. Through a review of the diagnostic and treatment paradigms for each disease, you will improve your ability to provide accurate and early diagnosis and appropriate therapy for your patients with these conditions. This activity will also highlight emerging options for treating patients with these rare blood disorders, clinical data, and expert interviews to help place emerging data into the context of clinical practice. The faculty share their best practices and review new and emerging strategies, and place novel data in the context of existing diagnostic and therapeutic algorithms.

Learning Objectives:
Upon successful completion of this activity, you should be better prepared to:
• Illustrate the importance of rigorous differential diagnoses for patients with rare hematologic disorders
• Detail the pathophysiology of multiple rare diseases with hematologic implications and how underlying biology informs treatment decisions
• Describe established evidence concerning treatment strategies to care for patients with thrombocytopenia or thrombosis resulting from rare blood disorders
• Incorporate methods to proactively mitigate the impact of disease- and treatment-related adverse events resulting from treating rare blood disorders

Additional details will be posted as soon as they are available.